"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
| Descriptor ID |
D013449
|
| MeSH Number(s) |
D02.065.884 D02.886.590.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 3 | 1 | 4 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 2 | 3 |
| 2009 | 2 | 2 | 4 |
| 2010 | 3 | 2 | 5 |
| 2011 | 5 | 2 | 7 |
| 2012 | 3 | 1 | 4 |
| 2013 | 4 | 1 | 5 |
| 2014 | 3 | 0 | 3 |
| 2016 | 0 | 1 | 1 |
| 2017 | 34 | 30 | 64 |
| 2018 | 40 | 47 | 87 |
| 2019 | 15 | 20 | 35 |
| 2020 | 13 | 21 | 34 |
| 2021 | 11 | 10 | 21 |
To return to the timeline, click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
Baricitinib as Treatment for Coronavirus Disease 2019 (COVID-19): Friend or Foe of the Pancreas? Clin Infect Dis. 2021 12 06; 73(11):e3977-e3978.
-
Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Clin Infect Dis. 2021 12 06; 73(11):e3978-e3979.
-
Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al. Clin Infect Dis. 2021 12 06; 73(11):e3980-e3981.
-
Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal? Rheumatology (Oxford). 2021 10 02; 60(10):e371.
-
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021 12; 9(12):1407-1418.
-
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. Lancet Respir Med. 2021 12; 9(12):1349-1351.
-
Using Nonheparin Anticoagulant to Treat a Near-Fatal Case With Multiple Venous Thrombotic Lesions During ChAdOx1 nCoV-19 Vaccination-Related Vaccine-Induced Immune Thrombotic Thrombocytopenia. Crit Care Med. 2021 09 01; 49(9):e870-e873.
-
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep; 22(5):693-707.
-
Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19. Respir Investig. 2021 Nov; 59(6):799-803.
-
Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2021 Oct; 99:108027.